Re-emerging infectious diseases

We are facing a world where microbes once again have the potential to cause untreatable diseases, due to the resistance to virtually all available drugs. WHO suggests that even if the pharmaceutical industry were to step up the efforts to develop new drugs immediately, some diseases might still not have any effective therapies within the next ten years.

How about proving them wrong?

Visiongain is dedicating its Re-emerging infectious diseases conference to the war on drug resistant microbes, uniting researchers from around the world in a unique exchange of thoughts, experiences and ideas. The conference will focus on the future of anti-microbial agents and will provide you with understanding of cutting edge research in:

DNA-based therapies
Novel beta-lactam inhibitors
New drug targets

Key Speakers:
David McIntosh, Medical Director, Infectious Diseases, Wyeth
Alita Miller, Senior Principal Scientist, Pfizer
Nachum Kaplan, Vice President, Microbiology, Affinium Pharmaceuticals
Anthony Maxwell, Head of the Department of Biological Chemistry, John Innes Centre
Michael McArthur, Director of Research, Procarta
John Overington, Senior Director, Discovery Informatics, Inpharmatica
Nafsika Georgopapadakou, Vice President, Research, NovaBay Pharmaceuticals
Lloyd Czaplewski, Director of Research, Prolysis
Malcolm Page, Head of Biology, Basilea Pharmaceuticals
Nora Kaarela, Chief Executive Officer, IPSAT Therapies
Prabhavathi Fernandes, CEO, Cempra Pharmaceuticals
Steve Barret, Honorary Secretary, Association of Medical Microbiologists
James Mond, Chief Scientific Officer, Executive Vice President, Biosynexus
Tanneke den Blaauwen, Assistant Professor, University of Amsterdam
Dr Ursula Theuretzbacher, Founder, Center for Anti-Infective Agents (CEFAIA)

Who will be there?
VPs Directors, Heads, and Managers in:
Microbiology
Immunology
Infectious Diseases
Medicinal Chemistry
Clinical Pharmacology
Drug Discovery
New Product Development
Scientific Affairs
Licensing
Antibiotics
Infection Discovery
Drug evaluation
Molecular Biotechnology
Drug development
Project Management
Preclinical Development
Portfolio Management

Weblink: www.visiongain.com